Non-Scarring Alopecia: Treatment Options and Comprehensive Overview

Hair loss, medically termed alopecia, can be an emotionally challenging experience, significantly impacting an individual's quality of life. As a board-certified dermatologist specializing in hair disorders for over 15 years, I understand the distress and potential life-altering effects of hair loss. At MD Hair Labs, our commitment lies in accurately diagnosing and effectively treating hair loss, employing both medical interventions and hair transplantation when necessary.

Alopecia is broadly categorized into two main types: scarring (cicatricial) and non-scarring (non-cicatricial). Scarring alopecia involves permanent damage to the hair follicles, replaced by scar tissue, leading to irreversible hair loss. In contrast, non-scarring alopecia involves hair loss or thinning, but the hair follicles remain intact, offering the potential for hair regrowth. This article focuses on non-scarring alopecia, exploring its various types, causes, and treatment options.

Understanding Non-Scarring Alopecia

Non-scarring alopecia is influenced by a spectrum of factors, including genetic predispositions, autoimmune conditions, hormonal imbalances, and nutritional deficiencies. Stress and lifestyle factors such as irregular eating habits, excessive alcohol consumption, and smoking can also contribute to hair loss.

Figure 1 delineates a detailed panorama of non-cicatricial alopecia, showcasing its various manifestations, including androgenetic alopecia, anagen effluvium, alopecia areata, telogen effluvium, trichotillomania, and loose anagen hair syndrome. Each subtype is distinguished by its own set of pathophysiological mechanisms, which are intricately interwoven. This visual dissection not only facilitates a deeper appreciation of the condition’s layered complexity but also accentuates the progressive strides in dermatological therapeutics.

Common Types of Non-Scarring Alopecia

1. Androgenetic Alopecia (AGA): Also known as male or female pattern baldness, AGA is the most common type of non-scarring alopecia. It affects approximately 80% of men and 40% of women under the age of 70 in the Caucasian population. AGA is characterized by the incremental reduction in the size of hair follicles, shortening the growth phase and extending the resting phase, culminating in the emergence of finer, less pigmented hairs across the scalp.

   Read also: Scarring Alopecia: An Overview

   • Causes: AGA is rooted in genetic, epigenetic, hormonal, and environmental influences, with genetics being particularly influential. Genome-Wide Association Studies (GWAS) have uncovered over 190 genetic markers associated with AGA, with the androgen receptor (AR) gene variants predominantly contributing to over 60% of the genetic predisposition. The conversion of testosterone (T) to Dihydrotestosterone (DHT) by 5α-reductase is a pivotal biochemical process in AGA, where DHT is identified as the principal mediator. DHT and T engage with the AR to initiate intracellular signaling cascades that modulate gene expression within the nucleus.
   • Diagnosis: Clinical assessment of AGA severity is conducted through established grading systems. The Hamilton-Norwood scale is utilized for MPHL, offering a detailed classification into various stages. For women, the Sinclair Scale or the Savin classification is applied, both of which assess the extent of hair thinning based on scalp density.

2. Telogen Effluvium (TE): This condition involves a shift of a large number of hairs in the growth (anagen) phase into the resting (telogen) phase. There are over 200,000 cases of TE per year in the US. TE can occur at any age and is caused by a shift of a large number of hairs in the growth (anagen) phase into the resting (telogen) phase.

   • Causes: The most common causes are physical or mental stressors, severe chronic illnesses, pregnancy, surgery, high fever, malnutrition, severe infections, and endocrine disorders. Postpartum women often experience this condition 3-4 months after giving birth.
   • Characteristics: Hair loss with telogen effluvium does not lead to total hair loss. Fortunately, the condition will stop before 50% of the hair is lost. In most cases, TE is completely reversible. With time and treatment of any underlying deficiency, or removal of the offending drug, hair loss stops and the hairs shift back into the anagen phase.

3. Alopecia Areata (AA): This is an autoimmune disease characterized by sudden, non-scarring hair loss. AA affects more than 2% of the world’s population and has a higher incidence rate in individuals aged 10-25 years.

   • Causes: The etiology of AA includes genetic factors, environmental factors, oxidative stress, and other factors, among which genetic factors play a dominant role.
   • Clinical Manifestations: The clinical manifestations of AA vary greatly. The Severity of Alopecia Tool (SALT) is often used to evaluate the severity of AA. A notable characteristic of AA is the presence of exclamation-mark-like hair, indicative of malnourishment. Depending on the extent of AA, it can be broadly divided into three types: patchy alopecia (AF), alopecia totalis (AT), and alopecia universalis (AU).
   • Pathological Mechanism: Patients with AA show infiltration of T lymphocyte subsets (CD56+NKG2D+NK cells) around the HFs in areas showing hair loss. Modern research indicates that IFN-γ secretion, the upregulation of NKG2D ligands (such as MICA and ULBP3/6), and the increased expression of MHC I and MHC II molecules and chemokines (such as IL-15, IL-2, and CXCLs) in HFs, all contribute to the failure of HF immune privilege

4. Anagen Effluvium: This type of hair loss occurs after radiation therapy to the head or systemic chemotherapy.

   • Causes: Both radiation and certain chemotherapy drugs cause damage to the hairs in the active growth phase or anagen phase. This damage causes hair shaft abnormalities or atypically shaped hairs that are broken off or shed from the follicle.
   • Characteristics: All hairs in the anagen phase are totally shed. Anagen effluvium is usually reversible, with regrowth one to three months after cessation of the offending agent. Permanent alopecia is rare.

5. Trichotillomania: This is an impulse-control disorder where individuals consciously or unconsciously pull, twist, or twirl their hair.

   • Characteristics: Patients typically present with frontoparietal patches of alopecia that progress posteriorly and may include the eyelashes and eyebrows. Bare patches are typical, and the hair may appear uneven, with twisted or broken off hairs.
   • Treatment: The optimal treatment for this condition is not known, and psychiatric referral may be indicated. Treatment options include cognitive behavior therapy and selective serotonin reuptake inhibitors.

6. Trichorrhexis Nodosa: This condition occurs when hairs break secondary to trauma or because of fragile hair.

   Read also: Comprehensive Guide to Alopecia Areata Treatment Ointments

   • Causes: Causative traumas include excessive brushing, heat application, tight hairstyles, trichotillomania, and conditions that cause excessive scalp scratching. Chemical traumas include harsh hair treatments and excessive exposure to salt water.
   • Characteristics: On examination, hairs appear to have white nodes; on closer inspection, these are shown to be fracture sites along the shaft and cortex that have split into several strands.

Treatment Options for Non-Scarring Alopecia

The treatment of non-scarring alopecia aims to address the underlying causes, promote hair regrowth, and improve the overall health of the hair follicles. Various treatment options are available, ranging from topical and oral medications to advanced therapies.

1. Topical Minoxidil: Approved for both men and women with AGA, topical minoxidil is available in 2% and 5% solutions. It stimulates hair regrowth, particularly at the vertex of the scalp. Consistent, long-term use is necessary to maintain results. Commercial formulations of this drug are currently solutions in alcohol or propylene glycol due to its poor water solubility, which may produce skin irritation such as scalp dryness, burning, redness, and allergic contact dermatitis, which interfere in the effectiveness of the therapy. Furthermore, formulations with ethanol as solvent are prone to promote the crystallization of the drug at the application site due to the solvent’s rapid evaporation, preventing its penetration into the skin.
2. Oral Finasteride: This medication is approved for men with AGA. Finasteride blocks the enzyme 5α-reductase, responsible for converting testosterone to DHT, resulting in a significant reduction in DHT concentration. Finasteride may lead to sexual dysfunction, erectile dysfunction, and gynecomastia.
3. Janus Kinase (JAK) Inhibitors: The use of JAK inhibitors (JAKi) can block the signal transduction of IFN-γ and effectively improve AA-like hair loss.
   • Ritlecitinib and Baricitinib: These drugs are approved by the US Food and Drug Administration (FDA) to treat alopecia.
4. Corticosteroids: Corticosteroids are often prescribed to reduce inflammation and suppress immune responses. They help soothe irritation and prevent further follicular damage. Regarding the corticosteroids, some major drawbacks of chronic, systemic treatment are the numerous adverse reactions, affecting nearly every organ system and metabolic process in the body.
5. Immunosuppressive Drugs: Immunosuppressive drugs may be used when autoimmune diseases are the underlying cause of scarring alopecia. These medications help control immune system activity, preventing it from attacking healthy hair follicles and causing further damage.
6. Antibiotics: Antibiotics may be prescribed if there is a bacterial infection in the follicles or pustules. They help treat infections that could worsen scarring alopecia and prevent further damage to the scalp.
7. Hair Transplantation: When a significant amount of hair loss has already occurred, medical management will likely not lead to significant cosmetic improvement alone, and a hair transplant may be necessary. Those considering a hair transplant must be committed to long-term medical management. For those with severe types of alopecia where the hair loss is permanent, a hair transplant could be considered once a loss has stabilized, assuming there is enough donor hair to replace the loss. Hair transplants can be a viable option for some patients. However, this treatment is more suitable when the scarring is stable and no active inflammation is present. The procedure involves relocating healthy hair follicles to areas affected by scarring.
8. Low-Level Laser Therapy (LLLT): This device is approved by the US Food and Drug Administration (FDA) to treat alopecia.
9. Wigs or Hairpieces: These provide a non-surgical solution to restore appearance while waiting for treatments to take effect or when hair restoration is not possible.

Novel Dermatological Formulations for Alopecia Treatment

Recent research has focused on developing novel dermatological formulations to address the limitations of existing treatments. These formulations aim to improve drug delivery, reduce side effects, and enhance patient compliance.

1. Nanoparticles: In general, these nanoparticles can reduce the irritant potential of drug molecules and control their release. Also, the colloids obtained with the aqueous dispersion of the nanostructures eliminate or at least considerably reduce the use of organic solvents or oil in the formulations, impacting both the reduction of toxicity and skin irritation, as well as the sensory acceptability of the product. Still, several studies have shown that topically applied nanoparticles tend to accumulate into hair follicles, which is a desirable outcome as this is the therapeutic target for alopecia.

   • Lipid Nanoparticles: This nanoparticle category is constituted by solid lipid nanoparticles, nanostructured lipid carriers, liposomes, and other lipid vesicles. These systems’ elastic characteristics are directly related to the fluidity of the lipid or phospholipid bilayer that compose them.
   • Polymeric Nanoparticles: This category of nanoparticles is constituted by fewer flexible matrices, such as polymers and metals, and exhibits useful characteristics for topical application, as greater stability along with a more substantial control of drug release in comparison with the deformable nanoparticles. Polymers like poly(lactic-co-glycolic) (PLGA), poly-ε-caprolactone, poly(d,l-lactide) (PLA) and chitosan have been often used as matrices to produce nanoparticles that encapsulate drugs for the topical treatment of alopecia, resulting in high skin biocompatibility approaches.

2. Energetic Drug Delivery Methods: Some studies have proposed iontophoresis and ultrasound as energetic drug delivery methods to favor topical therapy of alopecia.

   • Iontophoresis: Iontophoresis is a non-invasive technique that applies a small electric current (of no more than 0.5 mA/cm2) on the skin’s surface to increase and control drug delivery.
   • Sonophoresis: Sonophoresis, which consists of using ultrasound waves of low frequency to enhance transdermal dr…

The Role of Dermal Papilla Cells and Signaling Pathways

In the hair growth cycle, the dermal papilla (DP) is a central regulator of hair follicle (HF) regeneration. Examinations of scalp tissue samples from individuals with AGA have shown a correlation between increased DHT levels and heightened AR expression in dermal papillary cells (DPCs), particularly in areas affected by hair loss. This contrasts with the normal expression levels in unaffected regions.

Read also: Hair Loss Solutions for Black Men

Current research indicates that DHT can trigger DPCs to produce paracrine factors that downregulate the expression of growth-promoting factors such as insulin-like growth factor-1 (IGF-1), basic fibroblast growth factor (BFGF), and vascular endothelial growth factor (VEGF), while upregulating the expression of pro-apoptotic factors like transforming growth factor-β1 (TGF-β1), interleukin-1α (IL-1α), and tumor necrosis factor-α (TNF-α).

The Wnt/β-catenin signaling pathway is instrumental in the embryonic development and regeneration of hair follicles, promoting the onset of the growth phase. In contrast, the bone morphogenetic protein (BMP) signaling pathway exerts an inhibitory effect on the initiation of hair follicle growth. The delicate balance between these pathways is essential for the transition of HFs from the resting phase to the growth phase.

tags: #non #scarring #alopecia #treatment #options

---

---